Divergent RNA transcripts and estrogen signaling in breast cancer
Official title: Analysis of Divergent Transcripts in Estrogen-Dependent Signaling
Funded at University of Texas Rio Grande Valley · NIH-11415866 · Data updated 2026-11-12
Aims to understand how unusual RNA transcripts affect estrogen-driven growth in ER-positive breast cancer cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Rio Grande Valley NIH-funded |
| Lab location | 1 site (Edinburg, United States) |
| Project start | September 10, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $150,000 |
| NIH project number | 5R16GM149497-05 |
| Project ID | NIH-11415866 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with ER-positive breast cancer where estrogen signaling drives disease progression.
✕Less likely to help
If the cancer does not rely on estrogen signaling, results may be less directly applicable.
What this research studies
This project looks at how estrogen, through its receptor, triggers a set of transcripts that may control how breast cancer cells grow. Researchers will study the new divergent transcripts identified in earlier work to see how they influence estrogen- and androgen-related signaling. They will use cellular and genomic techniques to uncover the mechanisms by which these transcripts regulate gene expression and cell behavior. The goal is to reveal new molecular details that could point to novel targets for therapy in ER-positive breast cancer.
Why it matters
Potential benefit: Better understanding of estrogen-driven breast cancer biology could lead to new treatment approaches.
How similar studies have gone: Preliminary studies have identified E2-regulated divergent RNAs and begun characterizing one transcript, suggesting potential relevance.
Where this research is happening
-
University of Texas Rio Grande Valley
Edinburg, United States Active
Researchers
- Principal investigator: Gadad, Shrikanth — University of Texas Rio Grande Valley
- Study coordinator: Gadad, Shrikanth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.